Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
Of 25 patients with estrogen-unresponsive prostatic adenocarcinoma submitted to multi-drug chemotherapy 6 had partial objective regression, 12 had objectively stable disease and 7 had progressive disease. The survival rates in the 3 groups were 63, 52 and 40 weeks, respectively.